Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasmodium Immunotherapy in Advanced Breast and Liver Cancers
NCT03474822Phase 2Recruiting
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer and liver cancer, sponsored by CAS Lamvac Biotech Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events at 2 years. Started Aug 2018; status: recruiting.
02
Conditions
breast cancerliver cancer
Beyond the preview
Go deeper on NCT03474822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474822.